GlassScriptPhysician profile
Stephen M Selkirk
NPI 1184695801
$1,894.89
in general payments reported to CMS, 2019-2025
23 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.38 · 2020: $127 · 2021: $313 · 2022: $580 · 2023: $514 · 2024: $142 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.62 | 2021-2025 | Ubrelvy, Qulipta |
| Ucb, INC. | $232.87 | 2020-2023 | Nayzilam |
| Biohaven Pharmaceutical Holding Company LTD. | $153.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $117.73 | 2023-2025 | Tezspire, Breztri |
| Lilly USA, LLC | $88.63 | 2023 | Amyvid |
| Pfizer INC. | $75.44 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $63.28 | 2021-2023 | Ponvory |
| Biohaven Pharmaceuticals, INC. | $59.74 | 2021 | |
| Genentech USA, INC. | $57.53 | 2022-2023 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $48.12 | 2022 | |
| Tg Therapeutics, INC. | $47.55 | 2023 | |
| Allergan, INC. | $42.94 | 2020 | |
| Viatris Specialty LLC | $37.81 | 2025 | Yupelri |
| Averitas Pharma INC. | $29.89 | 2025 | Qutenza |
| Amgen INC. | $26.43 | 2023 | Aimovig |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Banner Life Sciences, LLC | $25.51 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.09 | 2021-2022 | |
| Eisai INC. | $21.75 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.55 | 2023 | Nuedexta |
| Glaxosmithkline, LLC. | $16.69 | 2025 | Trelegy Ellipta |
| Biogen, INC. | $15.38 | 2019 | |
| Validus Pharmaceuticals LLC | $15.36 | 2023 | Equetro |
| Avanir Pharmaceuticals, INC. | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Selkirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.